Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2474
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study ; volume:13 ; number:1 ; day:24 ; month:9 ; year:2012 ; pages:1-6 ; date:12.2012
BMC musculoskeletal disorders ; 13, Heft 1 (24.9.2012), 1-6, 12.2012
- Urheber
-
van der Maas, Aatke
- Beteiligte Personen und Organisationen
-
van den Bemt, Bart JF
Wolbink, Gertjan
van den Hoogen, Frank HJ
van Riel, Piet LCM
den Broeder, Alfons A.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2474-13-184
- URN
-
urn:nbn:de:1111-2016043022295
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- van der Maas, Aatke
- van den Bemt, Bart JF
- Wolbink, Gertjan
- van den Hoogen, Frank HJ
- van Riel, Piet LCM
- den Broeder, Alfons A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
PF-06438179/GP1111: An Infliximab Biosimilar
Infliximab-induced hot kidneys on bone scintigraphy
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
PF-06438179/GP1111: An Infliximab Biosimilar
Infliximab-induced hot kidneys on bone scintigraphy
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
PF-06438179/GP1111: An Infliximab Biosimilar
Infliximab-induced hot kidneys on bone scintigraphy
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars